Adult Dosing

Treatment of raised IOP

• 1 drop (1.5 mcg) in the affected eye(s) qd in the evening

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

• Hypersensitivity to any of the ingredients of the product
• Hypersensitivity to benzalkonium chloride

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• Latanoprost may cause increased pigmentation of the iris, periorbital tissue, and eyelashes; and growth of eyelashes. On discontinuation of therapy, all the reactions are reversible except pigmentation of the iris which is likely to be permanent
• Color of the eye changes due to increased melanin content in the stromal melanocytes of the iris rather than increase in the number of melanocytes; brown pigmentation around the pupil spreads concentrically towards periphery of the iris and entire or parts of iris become more brownish
• Changes in length, thickness, pigmentation, the number of lashes or hairs, and misdirected growth of eyelashes and vellus hair have occurred in the treated eye. These changes are reversible upon discontinuation of treatment
• Caution should be exercised in patients with a history of intraocular inflammation and should not be used in patients with active intraocular inflammation
• Macular edema and cystoid macular edema have been reported during treatment, use cautiously in pseudophakic patients who do not have an intact posterior capsule or who have known risk factors for macular edema
• Bacterial keratitis have been reported with the use of multiple-dose containers of topical ophthalmic products
• Remove the contact lenses prior to administration, can be reinserted 15 minutes after administration

Cautions: Use cautiously in

• History of intraocular inflammation
• Intact posterior capsule
• Risk factors for macular edema
• Aphakia

Supplemental Patient Information

• Do not touch the eyelids or surrounding areas with the dropper tip as this could contaminate the tip and result in serious ocular infections
• If more than one ophthalmic drugs are used, administer the drugs at least 5 minutes apart
• Contact lenses should be removed prior to administration of the drug
• Immediately contact physician if the patient develops any ocular reactions, particularly conjunctivitis and lid reactions
• If the patient develops an intercurrent ocular condition such as trauma or infection or in case of ocular surgery, consult a physician immediately regarding the continued use of the multiple-dose container

Pregnancy Category:C

Breastfeeding: Because of a short half-life, it is unlikely to cause any adverse effects in breastfed infants. To substantially diminish the amount of drug reaching the breast milk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more and remove the excess solution with an absorbent tissue. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 3 February 2011). Manufacturer advises caution.

• EENT: Macular edema, blurred vision, intraocular inflammation, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, punctate epithelial keratitis, dry eyes, excessive tearing, eye pain, lid crusting, lid discomfort/pain, lid edema, lid erythema, herpes keratitis, photophobia, increased pigmentation of the iris, eyelash and vellus hair changes
• CNS: Dizziness, headache
• DERM: Rash, pruritus, eyelid skin darkening, epidermal necrolysis
• RESP: Upper respiratory tract infections, cold
• CV: Chest pain, angina pectoris
• MUSC: Joint pain, back pain
• MISC: Flu

• Neuroprotective agent; it is a prostanoid selective FP receptor agonist, reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humor
• Metabolism: Primarily by the liver to 1,2-dinor and 1,2,3,4-tetranor metabolites
• Excretion: Urine (88%)
• Half-life: 17 mins

US Trade Name(s)

• Xalatan

US Availability

latanoprost (generic)

• OPTH SOLN: 0.005%

Xalatan

• OPTH SOLN: 0.005%

Canadian Trade Name(s)

• Xalatan

Canadian Availability

Xalatan

• OPTH SOLN: 0.005%

UK Trade Name(s)

• Xalatan

UK Availability

Xalatan

• OPTH SOLN: 0.005%

Australian Trade Name(s)

• Xalatan

Australian Availability

Xalatan

• OPTH SOLN: 0.005%

Ophthalmic

Ophthalmic Glaucoma Agents

Prostaglandin Analogs

Pricing data from www.DrugStore.com in U.S.A.

• Xalatan 0.005 % SOLN [Bottle] (PFIZER U.S.)
  2.5 % = $104.99
  7.5 % = $295.97
• Latanoprost 0.005 % SOLN [Pack] (SANDOZ)
  7.5 % = $56
  22.5 % = $149.97
• Latanoprost 0.005 % SOLN [Bottle] (GREENSTONE)
  2.5 % = $22.99
  7.5 % = $55.97

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.